TB-500: research reference

Separate result and explanation. Activity under particular conditions does not define a specification for every material using the same name.

Studies of full-length thymosin beta-4 describe interactions with actin. Finding part of its sequence in a fragment does not establish that both materials share a mechanism, exposure or results. Before applying that literature to TB-500, identify the molecule in the study preparation and the molecule documented for the batch.

The purity value is a product-label specification, not an assay result. A batch result can only be asserted from that batch’s certificate.

These names help identify the catalog entry. A descriptive label is not evidence of efficacy, and structural identity still requires appropriate documentation.

Actin peptide

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Personal protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

The name TB-500 does not establish molecular identity. An analytical study identified Ac-LKKTETQ, the 17–23 fragment of thymosin beta-4, in the product it analyzed (PMID 22962027); it does not identify Asciende’s vial. Full-length thymosin beta-4 references provide context and do not establish the effects, composition or equivalence of an uncharacterized commercial material.

The first question is identity. Full-length thymosin beta-4 has 43 residues; a 2012 analytical study identified the N-acetylated fragment Ac-LKKTETQ, corresponding to residues 17–23, in a product called TB-500. These are different materials. The article characterized the product received and synthesized a reference; it did not determine the composition of every vial using that name (PMID 22962027).

Asciende retains TB-500 as a catalog name but does not assign its vial the sequence, formula, molecular mass or CAS of full-length thymosin beta-4 without identity documentation. It does not reclassify the vial as the seven-residue fragment by analogy with that product either.

The collected bibliography includes thymosin beta-4 characterization, actin biochemistry and studies of specific clinical preparations. A phase I study examined recombinant human thymosin beta-4 in healthy volunteers (PMID 34346165); an ocular-surface study used an ophthalmic formulation (PMID 25826322). These materials and contexts must retain their names when describing results.

Those sources explain the scientific relationship with thymosin beta-4. They do not establish that a commercial ingredient called TB-500 is the same molecule or has the results observed with the full-length chain.

The presence of a region within a protein does not establish that an isolated fragment retains all its interactions, stability or distribution. The 2012 publication addressed an analytical question: identifying and characterizing a material. It was not a clinical trial comparing the fragment with full-length thymosin beta-4.

Half-lives, clinical outcomes and complete mechanisms therefore cannot be transferred between the two entities. Material sequence, chemical modifications and experimental preparation are necessary to select relevant literature.

BPC-157 + TB-500, GLOW and KLOW declare an ingredient using that name. Knowing which other ingredients a blend lists does not resolve TB-500 identity. Each ingredient and its proportions must be documented before comparison with a published preparation.

Isolated-ingredient literature also does not demonstrate synergy, compatibility or preservation of an individual profile after mixing. A rat combination study provides evidence about its model and preparation; it does not confirm the identity of Asciende’s formulation.

Useful documentation links the material name and batch to a full sequence, chemical modifications and analytical results capable of checking that identity. A purity percentage or abbreviated name alone does not distinguish the full-length chain from the fragment.

Until that link is established, this page leaves the vial’s molecular identifiers unassigned. The sources remain available to inspect which material was studied, by which method and what conclusion it supports; they are not a product certificate.